BON Debuts Groundbreaking Broccoli-Derived Sleep Wellness Line, Reshaping the Sleep Health Market through Innovative Technology
BON Natural Life Limited (Nasdaq: BON) has announced the launch of its innovative sleep health product series, featuring a patent-pending "Glucoraphanin-Myrosinase" delivery system. This breakthrough technology aims to enhance the bio-availability of glucoraphanin, a key compound found in broccoli that converts to sulforaphane in the body.
The company's proprietary system addresses the inefficient enzymatic conversion of glucoraphanin to sulforaphane, which typically limits the body's ability to access broccoli's full health benefits. Sulforaphane is associated with multiple health advantages, including sleep regulation, anti-cancer properties, and neuro-protective effects.
CEO Yongwei Hu emphasizes that BON's new sleep health products are designed to outperform traditional formulations through superior bio-availability and enhanced biological potency, positioning the company to capitalize on market opportunities in the sleep health sector.
BON Natural Life Limited (Nasdaq: BON) ha annunciato il lancio della sua innovativa linea di prodotti per la salute del sonno, caratterizzata da un sistema di rilascio brevettato in attesa di approvazione, il "Glucorafanin-Mirosinasi". Questa tecnologia rivoluzionaria mira a migliorare la biodisponibilità del glucorafanin, un composto chiave presente nel broccoli che si trasforma in sulforafano all’interno del corpo.
Il sistema proprietario dell’azienda risolve il problema della conversione enzimatica inefficiente del glucorafanin in sulforafano, che normalmente limita la capacità del corpo di sfruttare appieno i benefici salutari del broccoli. Il sulforafano è associato a molteplici vantaggi per la salute, tra cui la regolazione del sonno, proprietà anticancro e effetti neuroprotettivi.
Il CEO Yongwei Hu sottolinea che i nuovi prodotti per la salute del sonno di BON sono progettati per superare le formulazioni tradizionali grazie a una migliore biodisponibilità e a una potenza biologica aumentata, posizionando l’azienda per cogliere le opportunità di mercato nel settore della salute del sonno.
BON Natural Life Limited (Nasdaq: BON) ha anunciado el lanzamiento de su innovadora serie de productos para la salud del sueño, que cuenta con un sistema de entrega patentado y pendiente de aprobación, el "Glucorafanina-Mirosinasa". Esta tecnología revolucionaria busca mejorar la biodisponibilidad de la glucorafanina, un compuesto clave presente en el brócoli que se convierte en sulforafano dentro del cuerpo.
El sistema exclusivo de la compañía soluciona la conversión enzimática ineficiente de glucorafanina a sulforafano, que normalmente limita la capacidad del cuerpo para aprovechar al máximo los beneficios para la salud del brócoli. El sulforafano está asociado con múltiples beneficios para la salud, incluyendo la regulación del sueño, propiedades anticancerígenas y efectos neuroprotectores.
El CEO Yongwei Hu destaca que los nuevos productos para la salud del sueño de BON están diseñados para superar las formulaciones tradicionales mediante una mejor biodisponibilidad y una potencia biológica aumentada, posicionando a la empresa para aprovechar las oportunidades del mercado en el sector de la salud del sueño.
BON Natural Life Limited (나스닥: BON)은 특허 출원 중인 "글루코라파닌-미로시나제" 전달 시스템을 특징으로 하는 혁신적인 수면 건강 제품 시리즈를 출시했다고 발표했습니다. 이 획기적인 기술은 브로콜리에서 발견되는 주요 화합물인 글루코라파닌의 생체 이용률을 향상시키는 것을 목표로 하며, 체내에서 설포라판으로 전환됩니다.
회사의 독자적인 시스템은 글루코라파닌이 설포라판으로 효율적으로 전환되지 않는 문제를 해결하여, 일반적으로 브로콜리의 건강상의 이점을 온전히 활용하는 데 제한이 되는 효소 변환의 비효율성을 극복합니다. 설포라판은 수면 조절, 항암 효과, 신경 보호 효과 등 다양한 건강상의 이점과 관련이 있습니다.
CEO 용웨이 후는 BON의 새로운 수면 건강 제품이 기존 제형보다 우수한 생체 이용률과 향상된 생물학적 효능을 통해 뛰어난 성능을 발휘하도록 설계되었으며, 수면 건강 분야 시장 기회를 선점할 수 있는 위치에 있다고 강조했습니다.
BON Natural Life Limited (Nasdaq : BON) a annoncé le lancement de sa nouvelle gamme innovante de produits pour la santé du sommeil, dotée d’un système de délivrance breveté en instance, le « Glucoraphanine-Myrosinase ». Cette technologie révolutionnaire vise à améliorer la biodisponibilité de la glucoraphanine, un composé clé présent dans le brocoli, qui se transforme en sulforaphane dans l’organisme.
Le système exclusif de la société résout le problème de la conversion enzymatique inefficace de la glucoraphanine en sulforaphane, qui limite généralement la capacité de l’organisme à bénéficier pleinement des bienfaits du brocoli. Le sulforaphane est associé à de nombreux avantages pour la santé, notamment la régulation du sommeil, des propriétés anticancéreuses et des effets neuroprotecteurs.
Le PDG Yongwei Hu souligne que les nouveaux produits pour la santé du sommeil de BON ont été conçus pour surpasser les formulations traditionnelles grâce à une meilleure biodisponibilité et une puissance biologique accrue, positionnant ainsi l’entreprise pour saisir les opportunités du marché dans le secteur de la santé du sommeil.
BON Natural Life Limited (Nasdaq: BON) hat die Einführung seiner innovativen Schlafgesundheitsproduktreihe bekannt gegeben, die ein zum Patent angemeldetes "Glucoraphanin-Myrosinase"-Lieferungssystem enthält. Diese bahnbrechende Technologie zielt darauf ab, die Bioverfügbarkeit von Glucoraphanin zu verbessern, einer wichtigen Verbindung, die in Brokkoli vorkommt und im Körper zu Sulforaphan umgewandelt wird.
Das firmeneigene System behebt die ineffiziente enzymatische Umwandlung von Glucoraphanin zu Sulforaphan, die üblicherweise die Fähigkeit des Körpers einschränkt, die vollen gesundheitlichen Vorteile von Brokkoli zu nutzen. Sulforaphan wird mit mehreren gesundheitlichen Vorteilen in Verbindung gebracht, darunter Schlafregulation, krebshemmende Eigenschaften und neuroprotektive Effekte.
CEO Yongwei Hu betont, dass die neuen Schlafgesundheitsprodukte von BON darauf ausgelegt sind, herkömmliche Formulierungen durch überlegene Bioverfügbarkeit und gesteigerte biologische Wirksamkeit zu übertreffen, wodurch das Unternehmen gut positioniert ist, um Marktchancen im Bereich Schlafgesundheit zu nutzen.
- Patent-pending technology potentially solving bio-availability challenges in broccoli-derived compounds
- Potential market expansion through innovative sleep health product series
- Product addresses multiple health benefits beyond sleep, including anti-cancer and neuro-protective effects
- Proprietary technology could create competitive advantage in the health and wellness market
- Patent is still pending, not yet secured
- Product efficacy and market acceptance yet to be proven
- No specific revenue projections or timeline for market impact provided
Insights
BON's broccoli-derived sleep product leverages novel delivery technology, potentially creating new revenue streams in the sleep health market.
BON Natural Life's announcement represents a strategic expansion into the sleep wellness market through innovative biotechnology. The company's patent-pending "Glucoraphanin-Myrosinase" delivery system addresses a fundamental challenge in nutritional science: the inefficient conversion of glucoraphanin to sulforaphane in the human body.
The technical innovation here is significant. The natural conversion process of glucoraphanin to sulforaphane typically has poor bioavailability - meaning most of the potential health benefits from broccoli consumption go unrealized. BON's system appears designed to substantially improve this conversion efficiency, potentially unlocking the full spectrum of sulforaphane's reported benefits, particularly for sleep regulation.
This product launch strategically positions BON at the intersection of several growing markets: functional foods, sleep health solutions, and natural wellness products. The company is clearly targeting a value-added approach rather than competing as a commodity ingredient supplier.
From a commercial perspective, BON is making a calculated move by launching this as a branded product line rather than just supplying the technology to other manufacturers. This vertical integration could potentially capture higher margins if the product demonstrates clinical efficacy.
The patent-pending status adds a layer of potential intellectual property protection, though without details on patent scope or jurisdictions, it's difficult to assess how defensible this position will be against competitors. The sleep health market is attractive but competitive, with multiple approaches from pharmaceuticals to nutraceuticals vying for consumer attention.
XI’AN, China, May 13, 2025 (GLOBE NEWSWIRE) -- BON Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading provider of bio-ingredient solutions for the natural health and personal care sectors, today announced the groundbreaking launch of its sleep health product series. Developed using the proprietary “Glucoraphanin-Myrosinase” delivery system (patent-pending), the Company intends for this product to dramatically enhance the bio-activity (the extent to which something is absorbed and utilized by the body) of glucoraphanin, a vital bio-active compound in broccoli and will be launched under the Company’s owned brand.
Broccoli, a nutrient-rich superfood, contains glucoraphanin, a key bio-active compound that undergoes metabolic conversion into sulforaphane in the human body. Sulforaphane has been linked to multiple health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects. However, the enzymatic conversion of glucoraphanin into its active form, sulforaphane, is inefficient making it difficult for the body to fully utilize the health benefits of broccoli. This creates challenges for nutritional utilization and commercial application.
The Company believes its patent-pending “Glucoraphanin-Myrosinase” represents an innovative biotechnological delivery system. By ensuring optimal enzymatic activation in the body, it achieves an advanced conversion efficiency of bio-active sulforaphane. This system is intended to help resolve fundamental bio-availability challenges. With its precision-driven design, easy usage, and consumer-friendly format, the Company believes this advancement holds transformative potentials through re-positioning glucoraphanin-sulforaphane in the health and wellness market, which will allow the Company to capitalize on potential revenue opportunities.
“BON’s new sleep health products aim to outperform conventional formulations with superior bio-availability, enhanced biological potency, and consumer-friendly usability,” Mr. Yongwei Hu, Chairman and CEO of BON, emphasized. “Our Glucoraphanin-Myrosinase delivery system aims to combine scientific rigor with commercial potential. It addresses critical unmet needs in sleep health and, we believe, is primed for rapid market adoption. We anticipate that this series of new products will achieve market expansion, thereby bolstering the Company's business growth. Furthermore, the proliferation of this product category is intended to profoundly alter the dynamics of the sleep health market.”
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes", "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
What is BON's new sleep wellness product technology based on?
How does BON's Glucoraphanin-Myrosinase delivery system work?
What are the potential health benefits of BON's new sleep product?
When will BON's new sleep wellness products be available?
What makes BON's sleep product different from conventional sleep supplements?
